Abstract:Tumor immunotherapy, including immune checkpoint therapy, CAR T cell therapy, and TCR-T cell therapy, has made significant progress in the treatment of cancer. Recently, newly developed nanomaterials have also been applied to anti-tumor immunotherapy. Among them, extracellular vesicles (EVs) have been well-engineered in recent years due to their low immunogenicity, high stability, and wide distribution in biological fluids. Despite the recent development of several EVs-based cancer immunotherapies, their clinical efficacy remains limited. In this study, we have developed engineered EVs designed to mimic the function of antigen-presenting cells, which can co-deliver multiple immune-activation signals to tumor-associated T cells. We named these vesicles Antigen-presenting Extracellular Vesicles (AP-EVs). AP-EVs express a high level of MHC I-peptide complexes, costimulatory molecules, and surface-bound cytokines, allowing for the simultaneous presentation of multiple immune modulators to antigen-specific CD8+ T cells. AP-EVs promote the clonal expansion and differentiation of antigen-specific cytotoxic T lymphocytes, resulting in potent anticancer immune responses. Notably, our findings indicate that combination therapy involving AP-EVs and anti-PD-1 yields superior anticancer immunity against established tumors compared to anti-PD-1 monotherapy. This synergistic effect underscores the potential of our engineered EVs as a novel and highly effective strategy for cancer immunotherapy. Citation Format: Xiabing Lyu, Tomoyoshi Yamano, Shota Imai, Toan Van Le, Rikinari Hanayama. Surface-engineered extracellular vesicles to modulate antigen-specific T cell expansion for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7251.

Genetically engineered cell-derived nanovesicles for cancer immunotherapy

Engineered extracellular vesicles and their mimetics for cancer immunotherapy

Immune Cell-Derived Extracellular Vesicles – New Strategies in Cancer Immunotherapy

Extracellular Vesicles as an Advanced Delivery Biomaterial for Precision Cancer Immunotherapy

Engineered Extracellular Vesicles for Cancer Therapy

Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation

Engineered extracellular vesicles: potentials in cancer combination therapy

New approaches in extracellular vesicle engineering for improving the efficacy of anti-cancer therapies

Revolutionizing cancer treatment via bioengineered extracellular vesicles: Exploring nanovesicles to fully synthetic solutions

Extracellular vesicles as next generation immunotherapeutics

Engineered extracellular vesicles: A new approach for targeted therapy of tumors and overcoming drug resistance

New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment

Surface-Engineered Extracellular Vesicles in Cancer Immunotherapy

Extracellular vesicles reshape the tumor microenvironment to improve cancer immunotherapy: Current knowledge and future prospects

Extracellular Vesicles as Delivery Vehicles for Therapeutic Nucleic Acids in Cancer Gene Therapy: Progress and Challenges

Abstract 7251: Surface-engineered extracellular vesicles to modulate antigen-specific T cell expansion for cancer immunotherapy

Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy

Extracellular vesicle-based macromolecule delivery systems in cancer immunotherapy

Extracellular vesicles as drug vectors for precise cancer treatment.

Extracellular vesicles derived from immune cells: Role in tumor therapy

Extracellular vesicles for cancer therapy: potential, progress, and clinical challenges